Rare and Atypical Diabetes Network

Description

RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes. The objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to: 1. Identify and enroll individuals and families with undiagnosed rare and atypical forms of diabetes. 2. Determine the etiologic basis of the metabolic disorder among individuals and families with novel forms of rare and atypical diabetes. 3. Understand the pathophysiology of individuals and families with novel forms of rare and atypical forms of diabetes.

Conditions

Diabetes Mellitus, Diabetes Mellitus Progression, Glucose Intolerance, Glucose Metabolism Disorders, Metabolic Disease, Endocrine; Complications, Endocrine System Diseases

Study Overview

Study Details

Study overview

RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes. The objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to: 1. Identify and enroll individuals and families with undiagnosed rare and atypical forms of diabetes. 2. Determine the etiologic basis of the metabolic disorder among individuals and families with novel forms of rare and atypical diabetes. 3. Understand the pathophysiology of individuals and families with novel forms of rare and atypical forms of diabetes.

Rare and Atypical Diabetes Network

Rare and Atypical Diabetes Network

Condition
Diabetes Mellitus
Intervention / Treatment

-

Contacts and Locations

Aurora

University of Colorado- Denver, Aurora, Colorado, United States, 80045

Chicago

University of Chicago, Chicago, Illinois, United States, 60637

Indianapolis

Indiana University, Indianapolis, Indiana, United States, 46202

Baltimore

University of Maryland, Baltimore, Maryland, United States, 21201

Boston

Massachusetts General Hospital (MGH), Boston, Massachusetts, United States, 02114

Ann Arbor

University of Michigan, Ann Arbor, Michigan, United States, 48109

Saint Louis

Washington University in St. Louis, Saint Louis, Missouri, United States, 63110

Brooklyn

SUNY Downstate Health Sciences University, Brooklyn, New York, United States, 11203

New York

Columbia University, New York, New York, United States, 10032

Chapel Hill

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States, 27514

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Type 2 diabetes diagnosed at a time when the individual was prepubertal or non-obese
  • * Mendelian pattern, especially with early onset (\<18 years old)
  • * Syndromic (multiple systems involved)
  • * Lipodystrophic
  • * Extremes of BMI
  • * "Mitochondrial" characteristics (e.g., myopathy, hearing deficits)
  • * Non-progressive
  • * Rapidly progressive ("fulminant")
  • * Low insulin requirements (\<0.5 u/kg/day)
  • * Cyclical hyperglycemia with periods of remission
  • * Lean persons with polycystic ovarian syndrome (PCOS)
  • * History of gestational diabetes (GDM) when lean
  • * Lean insulin-resistant persons
  • * If islet autoantibodies and beta-cell function parameters have been measured (where "A" = islet cell autoantibodies, "B" = beta-cell function):
  • * Those with high likelihood of typical type 1, typical type 2, known monogenic, or other known secondary forms of diabetes
  • * Refusal of consent for genetic testing
  • * Islet autoantibody positive (participants who are islet autoantibody positive but present with additional atypical features i.e. syndromic, strong linear family history of diabetes may not be excluded)
  • * Women who are currently pregnant

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of South Florida,

Jeffrey Krischer, PhD, STUDY_CHAIR, University of South Florida

Study Record Dates

2030-09